FinTechFunding

TearClear: Raises $22M in Series B Funding

  • TearClear Raises $22M in Series B Funding
  • TearClear, a Boston, MA-based ophthalmic pharmaceutical company, raised $22M in a Series B funding round
  • Bluestem Capital and Flying L Partners, who collaborated with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology
  • Then the company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications
  • Led by Chief Executive Officer Robert Dempsey, TearClear is an ophthalmic pharmaceutical company advancing two lead product candidates in glaucoma
  • The company also announced the appointment of Stuart Raetzman, who most recently served as Chief Executive Officer of Galderma, to the TearClear Board of Directors
Previous article
Westpac: Hires Scott Collary as new COO
Next article
Vmoto: Raises $9.6M to speed up growth opportunities
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Firenze Raises $6M to Strengthen Lombard Lending for Mass Affluent

Funding aims to enhance lending solutions for wealth management.Highlights: Firenze has raised $6 million in funding.The investment will...
FinTech

Fundtech Strengthens Leadership at Payments Infrastructure Provider Otoma

Fundtech appoints a new management team to enhance Otoma's operations.Highlights: Fundtech has appointed a new management team at...
FinTech

Ripple Strengthens Post-Quantum Readiness for XRP Ledger by 2028

Focus on enhancing security measures against future quantum computing threats.Highlights: Ripple plans to prepare the XRP Ledger for...
FinTech

New York Suits Coinbase and Gemini Over Prediction Markets

The state targets two major crypto exchanges regarding regulatory compliance.Highlights: New York has filed lawsuits against Coinbase and...